Perkenalan
Halaman ini memberikan analisis komprehensif tentang riwayat insider trading yang diketahui di Robert Alexander Ingram. Insider adalah pejabat, direktur, atau investor penting dalam suatu perusahaan. Adalah ilegal bagi insider untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik dan non-publik. Hal ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan ke SEC melalui Formulir 4. Meskipun ada pembatasan ini, penelitian akademis menunjukkan bahwa insider – secara umum – cenderung mengungguli pasar di perusahaan mereka sendiri.
Profitabilitas Perdagangan Rata-rata
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari seluruh pembelian pasar terbuka yang dilakukan oleh insider dalam 3 tahun terakhir. Untuk menghitungnya, kami memeriksa setiap pembelian pasar terbuka dan tidak terencana yang dilakukan oleh insider, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata perdagangan tersebut selama 3, 6, dan 12 bulan, merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami menghitung rata-rata semua metrik kinerja untuk menghitung metrik kinerja bagi insider. Daftar ini hanya mencakup insider yang telah melakukan setidaknya tiga perdagangan dalam 2 tahun terakhir.
Jika profitabilitas perdagangan insider ini adalah "T/A", maka insider tersebut belum melakukan pembelian di pasar terbuka dalam 3 tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang dapat diandalkan.
Frekuensi Pembaruan: Harian
Perusahaan dengan Posisi Insider yang Dilaporkan
Pengajuan SEC menunjukkan Robert Alexander Ingram telah melaporkan kepemilikan atau perdagangan di perusahaan berikut:
| Keamanan | Judul | Kepemilikan Terbaru yang Dilaporkan |
|---|---|---|
| US:BCRX / BioCryst Pharmaceuticals, Inc. | Director | 100.198 |
| US:BDTX / Black Diamond Therapeutics, Inc. | 42.854 | |
| US:NOVN / Novan Inc | Director | 20.000 |
| US:PHAS / PhaseBio Pharmaceuticals Inc | 10% Owner | 0 |
| US:CREE / Cree, Inc. | Director | 77.710 |
| US:GTHX / G1 Therapeutics, Inc. | 10% Owner | 3.237.711 |
| US:BHC / Bausch Health Companies Inc. | Director | 92.046 |
| US:CLSD / Clearside Biomedical, Inc. | 10% Owner | 2.060.514 |
| US:REGN / Regeneron Pharmaceuticals, Inc. | Director | 1.500 |
| US:EW / Edwards Lifesciences Corporation | Director | 32.367 |
| Director | 8.613 | |
| US:LOW / Lowe's Companies, Inc. | Director | 7.274 |
Bagaimana Menafsirkan Grafik
Bagan berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka dan tidak terencana yang dilakukan oleh Robert Alexander Ingram. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham dipetakan sebagai persentase perubahan kumulatif harga saham. Misalnya, jika perdagangan insider dilakukan pada tanggal 1 Januari 2019, grafik akan menunjukkan persentase perubahan harian sekuritas hingga hari ini. Jika harga saham naik dari $10 menjadi $15 selama waktu ini, persentase perubahan harga saham kumulatif akan menjadi 50%. Perubahan harga dari $10 menjadi $20 adalah 100%, dan perubahan harga dari $10 menjadi $5 adalah -50%.
Pada akhirnya, kami mencoba untuk menentukan seberapa dekat korelasi perdagangan insider dengan keuntungan berlebih (positif atau negatif) pada harga saham untuk melihat apakah insider mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi insider. Pertimbangkan situasi di mana insider melakukan hal ini. Dalam situasi ini, kita mengharapkan (a) keuntungan positif setelah pembelian, atau (b) keuntungan negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, yang menunjukkan keuntungan positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, yang menunjukkan keuntungan negatif setelah setiap transaksi penjualan.
Namun, hal ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam kenaikan non-siklus selama bertahun-tahun, maka kita perkirakan semua lahan pasca pembelian akan miring ke atas. Demikian pula, penurunan non-siklus selama bertahun-tahun akan mengakibatkan penurunan pasca-perdagangan. Tak satu pun dari grafik ini menunjukkan aktivitas insider trading.
Indikator terkuat adalah situasi di mana harga saham sangat bersiklus, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat memberi isyarat kepada insider yang mengatur waktu perdagangan demi keuntungan finansial mereka.
Pembelian Insider BCRX / BioCryst Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada BCRX / BioCryst Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-11-18 | BCRX | INGRAM ROBERT ALEXANDER | 20.000 | 1,4500 | 20.000 | 1,4500 | 29.000 | 184 | 5.61 | 83.200 | 286,90 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider BCRX / BioCryst Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di BCRX / BioCryst Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider BDTX / Black Diamond Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada BCRX / BioCryst Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | BDTX | INGRAM ROBERT ALEXANDER | 5.000 | 30,4570 | 5.000 | 30,4570 | 152.285 | 42 | 35.0000 | 22.715 | 14,92 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider BDTX / Black Diamond Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di BCRX / BioCryst Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider BHC / Bausch Health Companies Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada BCRX / BioCryst Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider BHC / Bausch Health Companies Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di BCRX / BioCryst Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider CLSDQ / Clearside Biomedical, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada BCRX / BioCryst Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider CLSDQ / Clearside Biomedical, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di BCRX / BioCryst Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider WOLF / Wolfspeed, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada BCRX / BioCryst Pharmaceuticals, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009-03-06 | CREE | INGRAM ROBERT ALEXANDER | 1.000 | 18,9486 | 1.000 | 18,9486 | 18.949 | 360 | 69.71 | 50.762 | 267,90 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider WOLF / Wolfspeed, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di BCRX / BioCryst Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-12-01 | CREE | INGRAM ROBERT ALEXANDER | 3.750 | 27,6680 | 3.750 | 27,6680 | 103.755 | 338 | 21.1200 | -24.555 | -23,67 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Riwayat Insider Trading
Tabel ini menunjukkan daftar lengkap perdagangan insider yang dilakukan oleh Robert Alexander Ingram sebagaimana diungkapkan kepada Securities Exchange Commission (SEC).
| Tanggal Berkas | Tanggal Trans | Formulir | Kode | Keamanan | Kode | Saham | Sisa Saham | Persen Mengubah |
Saham Harga |
Trans Nilai |
Tersisa Nilai |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 2.259 | 100.198 | 2,31 | 8,85 | 19.992 | 886.752 | |
| 2022-12-19 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 9.375 | 42.854 | 28,00 | 1,50 | 14.062 | 64.281 | |
| 2022-12-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.497 | 97.939 | 1,55 | 13,36 | 20.000 | 1.308.465 | |
| 2022-09-19 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 6.584 | 33.479 | 24,48 | 2,62 | 17.250 | 87.715 | |
| 2022-09-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.438 | 96.442 | 1,51 | 13,90 | 19.988 | 1.340.544 | |
| 2022-06-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 8.498 | 26.895 | 46,19 | 2,03 | 17.251 | 54.597 | |
| 2022-06-09 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 12.866 | 95.004 | 15,66 | ||||
| 2022-06-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 2.078 | 82.138 | 2,60 | 9,31 | 19.346 | 764.705 | |
| 2022-03-18 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 5.795 | 18.397 | 45,98 | 3,02 | 17.501 | 55.559 | |
| 2022-03-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.128 | 80.060 | 1,43 | 16,61 | 18.736 | 1.329.797 | |
| 2021-12-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 3.296 | 12.602 | 35,42 | 5,31 | 17.502 | 66.917 | |
| 2021-12-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.554 | 78.932 | 2,01 | 12,06 | 18.741 | 951.920 | |
| 2021-09-23 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 1.869 | 9.306 | 25,13 | 9,90 | 18.503 | 92.129 | |
| 2021-09-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.177 | 77.378 | 1,54 | 15,92 | 18.738 | 1.231.858 | |
| 2021-06-22 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 15.000 | 15.000 | |||||
| 2021-06-22 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 1.255 | 7.437 | 20,30 | 12,95 | 16.252 | 96.309 | |
| 2021-06-01 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.188 | 76.201 | 1,58 | 15,77 | 18.735 | 1.201.690 | |
| 2021-05-27 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 40.000 | 40.000 | |||||
| 2021-03-22 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 677 | 6.182 | 12,30 | 24,01 | 16.255 | 148.430 | |
| 2021-03-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.739 | 75.013 | 2,37 | 10,78 | 18.746 | 808.640 | |
| 2020-12-16 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
A - Award | 505 | 5.505 | 10,10 | 34,29 | 17.316 | 188.766 | |
| 2020-12-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 3.669 | 73.274 | 5,27 | 5,11 | 18.749 | 374.430 | |
| 2020-10-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
P - Purchase | 5.000 | 5.000 | 30,46 | 152.285 | 152.285 | ||
| 2020-09-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 29.842 | 29.842 | |||||
| 2020-09-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 4.518 | 69.605 | 6,94 | 4,15 | 18.750 | 288.861 | |
| 2020-07-30 |
|
4 | NOVN |
Novan, Inc.
Stock Option (Right to Buy) |
A - Award | 20.000 | 20.000 | |||||
| 2020-06-03 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 4.171 | 65.087 | 6,85 | 4,50 | 18.749 | 292.566 | |
| 2020-05-14 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 40.000 | 40.000 | |||||
| 2020-03-03 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 6.250 | 60.916 | 11,43 | 3,00 | 18.750 | 182.748 | |
| 2019-12-03 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 6.578 | 54.666 | 13,68 | 2,85 | 18.747 | 155.798 | |
| 2019-11-18 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
P - Purchase | 20.000 | 48.088 | 71,20 | 1,45 | 29.000 | 69.728 | |
| 2019-09-04 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 6.270 | 28.088 | 28,74 | 2,99 | 18.747 | 83.983 | |
| 2019-08-02 |
|
4 | NOVN |
Novan, Inc.
Stock Option (Right to Buy) |
A - Award | 20.000 | 20.000 | |||||
| 2019-05-31 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 30.000 | 30.000 | |||||
| 2019-05-23 |
|
4 | NOVN |
Novan, Inc.
Common Stock |
P - Purchase | 50.000 | 169.777 | 41,74 | 2,21 | 110.500 | 375.207 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | -226.061 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | -24.709 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | -272.107 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -40.420 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -13.558 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -149.320 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -94.874 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -1.044.764 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock |
C - Conversion | -13.609 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock |
C - Conversion | -174.699 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | -4.846 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | -3.862 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | -42.530 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | -52.690 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | -994 | 40.420 | -2,40 | 5,00 | -4.970 | 202.100 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
X - Other | 41.414 | 41.414 | 0,12 | 4.970 | 4.970 | ||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
X - Other | -41.414 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | -104 | 13.558 | -0,76 | 5,00 | -520 | 67.790 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
X - Other | 4.309 | 13.662 | 46,07 | 0,12 | 517 | 1.639 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
X - Other | -4.309 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | -1.139 | 149.320 | -0,76 | 5,00 | -5.695 | 746.600 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
X - Other | 47.458 | 150.459 | 46,08 | 0,12 | 5.695 | 18.055 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
X - Other | -47.458 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
S - Sale | -42 | 94.874 | -0,04 | 5,00 | -210 | 474.370 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
X - Other | 1.731 | 94.916 | 1,86 | 0,12 | 208 | 11.390 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock |
X - Other | -1.731 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
S - Sale | -458 | 1.044.764 | -0,04 | 5,00 | -2.290 | 5.223.820 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
X - Other | 19.061 | 1.045.222 | 1,86 | 0,12 | 2.287 | 125.427 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock |
X - Other | -19.061 | 0 | -100,00 | ||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 150.000 | 416.481 | 56,29 | 5,00 | 750.000 | 2.082.405 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 266.481 | 266.481 | |||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 4.846 | 4.846 | |||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 12.487 | 163.099 | 8,29 | 5,00 | 62.435 | 815.495 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 150.612 | 150.612 | |||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 137.513 | 1.820.933 | 8,17 | 5,00 | 687.565 | 9.104.665 | |
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.683.420 | 1.683.420 | |||||
| 2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 52.690 | 52.690 | |||||
| 2018-10-18 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 760 | 77.710 | 0,99 | 39,46 | 29.990 | 3.066.437 | |
| 2018-10-01 |
|
4 | NOVN |
Novan, Inc.
Common Stock |
P - Purchase | 50.000 | 119.777 | 71,66 | 2,84 | 142.000 | 340.167 | |
| 2018-08-31 |
|
4 | CREE |
CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY) |
M - Exercise | -4.000 | 0 | -100,00 | 30,92 | -123.680 | ||
| 2018-08-31 |
|
4 | CREE |
CREE INC
COMMON STOCK |
M - Exercise | 4.000 | 76.950 | 5,48 | 30,92 | 123.680 | 2.379.294 | |
| 2018-08-16 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 648 | 72.950 | 0,90 | 46,26 | 29.976 | 3.374.667 | |
| 2018-06-22 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 30.000 | 30.000 | |||||
| 2018-06-07 |
|
4 | NOVN |
Novan, Inc.
Stock Option (Right to Buy) |
A - Award | 20.000 | 20.000 | |||||
| 2018-06-04 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 2.916 | 21.818 | 15,43 | 6,43 | 18.750 | 140.290 | |
| 2018-06-01 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -41.710 | 3.237.711 | -1,27 | 48,00 | -2.002.080 | 155.410.128 | |
| 2018-06-01 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -758.290 | 3.279.421 | -18,78 | 48,00 | -36.397.920 | 157.412.208 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -26 | 4.037.711 | 0,00 | 50,50 | -1.313 | 203.904.406 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -474 | 4.037.737 | -0,01 | 50,50 | -23.937 | 203.905.718 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -308 | 4.038.211 | -0,01 | 50,69 | -15.611 | 204.677.128 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -5.592 | 4.038.519 | -0,14 | 50,86 | -284.405 | 205.396.249 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -26 | 4.044.111 | 0,00 | 52,13 | -1.355 | 210.819.506 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -474 | 4.044.137 | -0,01 | 52,13 | -24.710 | 210.820.862 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -1.595 | 4.044.611 | -0,04 | 51,06 | -81.439 | 206.513.389 | |
| 2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | -29.005 | 4.046.206 | -0,71 | 51,16 | -1.483.907 | 207.005.517 | |
| 2018-04-27 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 764 | 72.302 | 1,07 | 39,25 | 29.987 | 2.837.854 | |
| 2018-03-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 3.772 | 18.902 | 24,93 | 4,97 | 18.747 | 93.943 | |
| 2018-01-26 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 833 | 71.538 | 1,18 | 35,98 | 29.971 | 2.573.937 | |
| 2017-12-04 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 3.690 | 15.130 | 32,26 | 5,08 | 18.745 | 76.860 | |
| 2017-12-04 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
J - Other | 995 | 4.075.211 | 0,02 | ||||
| 2017-12-04 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
J - Other | -99.513 | 4.074.216 | -2,38 | ||||
| 2017-10-20 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 731 | 70.705 | 1,04 | 34,16 | 24.971 | 2.415.283 | |
| 2017-09-06 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 7.033 | 69.974 | 11,17 | ||||
| 2017-09-05 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 3.676 | 11.440 | 47,35 | 5,10 | 18.748 | 58.344 | |
| 2017-08-29 |
|
4 | NOVN |
Novan, Inc.
Common Stock |
P - Purchase | 8.465 | 69.777 | 13,81 | 4,70 | 39.786 | 327.952 | |
| 2017-08-29 |
|
4 | NOVN |
Novan, Inc.
Common Stock |
P - Purchase | 3.535 | 61.312 | 6,12 | 4,25 | 15.024 | 260.576 | |
| 2017-08-24 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.125 | 62.941 | 1,82 | 22,21 | 24.986 | 1.397.920 | |
| 2017-06-07 |
|
4 | NOVN |
Novan, Inc.
Stock Option (right to buy) |
A - Award | 34.014 | 34.014 | |||||
| 2017-06-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.941 | 7.764 | 33,33 | 5,15 | 9.996 | 39.985 | |
| 2017-05-25 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 30.000 | 30.000 | |||||
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.009.693 | 0 | -100,00 | ||||
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -2.584.959 | 0 | -100,00 | ||||
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -6.568.527 | 0 | -100,00 | ||||
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -1.318.681 | 0 | -100,00 | ||||
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
P - Purchase | 133.333 | 3.861.797 | 3,58 | 15,00 | 1.999.995 | 57.926.955 | |
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
C - Conversion | 99.513 | 99.513 | |||||
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
C - Conversion | 212.419 | 212.419 | |||||
| 2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
C - Conversion | 3.728.464 | 3.728.464 | |||||
| 2017-04-27 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.132 | 61.816 | 1,87 | 22,07 | 24.983 | 1.364.279 | |
| 2017-04-04 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 2.120 | 92.046 | 2,36 | 11,03 | 23.384 | 1.015.267 | |
| 2017-03-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.602 | 5.823 | 37,95 | 6,24 | 9.996 | 36.336 | |
| 2017-01-26 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 867 | 60.684 | 1,45 | 28,83 | 24.996 | 1.749.520 | |
| 2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -7.592 | 2.060.514 | -0,37 | 8,22 | -62.406 | 16.937.425 | |
| 2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -12.258 | 2.068.106 | -0,59 | 8,64 | -105.909 | 17.868.436 | |
| 2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -9.806 | 2.080.364 | -0,47 | 8,92 | -87.470 | 18.556.847 | |
| 2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -6.478 | 1.757.719 | -0,37 | 8,22 | -53.249 | 14.448.450 | |
| 2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -10.457 | 1.764.197 | -0,59 | 8,64 | -90.348 | 15.242.662 | |
| 2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -8.366 | 1.774.654 | -0,47 | 8,92 | -74.625 | 15.829.914 | |
| 2017-01-04 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 1.463 | 89.926 | 1,65 | 14,52 | 21.243 | 1.305.726 | |
| 2016-12-02 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 1.788 | 4.221 | 73,49 | 5,59 | 9.995 | 23.595 | |
| 2016-10-20 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.115 | 59.817 | 1,90 | 22,41 | 24.987 | 1.340.499 | |
| 2016-10-05 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 865 | 88.463 | 0,99 | 24,55 | 21.236 | 2.171.767 | |
| 2016-09-28 |
|
4 | NOVN |
Novan, Inc.
Series 4 Preferred Stock |
C - Conversion | -27.777 | 0 | -100,00 | ||||
| 2016-09-28 |
|
4 | NOVN |
Novan, Inc.
Common Stock |
C - Conversion | 27.777 | 57.777 | 92,59 | ||||
| 2016-09-22 |
|
4 | NOVN |
Novan, Inc.
Stock Option |
A - Award | 14.484 | 14.484 | |||||
| 2016-09-20 | 3 | NONE |
Novan, Inc.
Common Stock |
60.000 | ||||||||
| 2016-09-20 | 3 | NONE |
Novan, Inc.
Common Stock |
60.000 | ||||||||
| 2016-09-06 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 6.429 | 58.702 | 12,30 | ||||
| 2016-09-06 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Common Stock |
A - Award | 2.433 | 2.433 | 4,11 | 10.000 | 10.000 | ||
| 2016-08-18 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.229 | 52.273 | 2,41 | 23,38 | 28.734 | 1.222.143 | |
| 2016-07-11 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 1.080 | 87.598 | 1,25 | 20,14 | 21.751 | 1.764.224 | |
| 2016-06-21 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 16.726 | 86.518 | 23,97 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -21.705 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series C Preferred Stock |
C - Conversion | -337.897 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series B Preferred Stock |
C - Conversion | -432.941 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A-1 Preferred Stock |
C - Conversion | -689.388 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A Preferred Stock |
C - Conversion | -2.035.908 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 414.286 | 2.090.170 | 24,72 | 7,00 | 2.900.002 | 14.631.190 | |
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -69 | 1.675.884 | 0,00 | 7,00 | -483 | 11.731.188 | |
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
X - Other | 21.705 | 1.675.953 | 1,31 | 0,02 | 478 | 36.871 | |
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
C - Conversion | 1.598.223 | 1.654.248 | 2.852,70 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1.805 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -19.900 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series C Preferred Stock |
C - Conversion | -337.898 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series B Preferred Stock |
C - Conversion | -432.940 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A-1 Preferred Stock |
C - Conversion | -689.388 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A Preferred Stock |
C - Conversion | -2.035.907 | 0 | -100,00 | ||||
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 107.142 | 1.783.020 | 6,39 | 7,00 | 749.994 | 12.481.140 | |
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | -69 | 1.675.878 | 0,00 | 7,00 | -483 | 11.731.146 | |
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
X - Other | 21.705 | 1.675.947 | 1,31 | 0,02 | 478 | 36.871 | |
| 2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
C - Conversion | 1.598.219 | 1.654.242 | 2.852,79 | ||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.050 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112.046 | ||||||||
| 2016-05-25 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 30.000 | 30.000 | |||||
| 2016-05-04 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 926 | 69.792 | 1,34 | ||||
| 2016-04-29 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.105 | 51.044 | 2,21 | 26,00 | 28.730 | 1.327.144 | |
| 2016-01-22 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.093 | 49.939 | 2,24 | 26,30 | 28.746 | 1.313.396 | |
| 2016-01-04 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 239 | 68.866 | 0,35 | ||||
| 2015-12-03 |
|
4 | CREE |
CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY) |
M - Exercise | -3.750 | 0 | -100,00 | ||||
| 2015-12-03 |
|
4 | CREE |
CREE INC
COMMON STOCK |
S - Sale | -3.750 | 48.846 | -7,13 | 27,67 | -103.755 | 1.351.471 | |
| 2015-12-03 |
|
4 | CREE |
CREE INC
COMMON STOCK |
M - Exercise | 3.750 | 52.596 | 7,68 | 14,71 | 55.162 | 773.687 | |
| 2015-10-23 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.199 | 48.846 | 2,52 | 23,96 | 28.728 | 1.170.350 | |
| 2015-10-02 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 136 | 68.627 | 0,20 | ||||
| 2015-09-03 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 6.674 | 47.647 | 16,29 | ||||
| 2015-08-14 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 1.112 | 40.973 | 2,79 | 26,58 | 29.557 | 1.089.062 | |
| 2015-08-07 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Non-Qualified Stock Option |
A - Award | 18.750 | 18.750 | |||||
| 2015-07-02 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 109 | 68.491 | 0,16 | ||||
| 2015-05-27 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 1.607 | 68.382 | 2,41 | ||||
| 2015-05-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | -1.379 | 1.500 | -47,90 | 513,39 | -707.965 | 770.085 | |
| 2015-05-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | -6.667 | 13.333 | -33,34 | ||||
| 2015-05-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
F - Taxes | -3.788 | 2.879 | -56,82 | 516,48 | -1.956.426 | 1.486.946 | |
| 2015-05-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6.667 | 6.667 | 293,53 | 1.956.965 | 1.956.965 | ||
| 2015-05-19 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 305 | 32.367 | 0,95 | ||||
| 2015-05-19 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 1.521 | 32.062 | 4,98 | ||||
| 2015-04-24 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 811 | 39.861 | 2,08 | 32,36 | 26.244 | 1.289.902 | |
| 2015-04-02 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 122 | 66.775 | 0,18 | ||||
| 2015-01-23 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 775 | 39.050 | 2,02 | 33,87 | 26.249 | 1.322.624 | |
| 2015-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 10.838 | 10.838 | |||||
| 2014-10-24 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 962 | 38.275 | 2,58 | 27,27 | 26.234 | 1.043.759 | |
| 2014-09-04 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 4.244 | 37.313 | 12,83 | ||||
| 2014-08-15 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 390 | 33.069 | 1,19 | 44,81 | 17.476 | 1.481.822 | |
| 2014-08-01 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
S - Sale | -12.500 | 30.541 | -29,04 | 90,26 | -1.128.279 | 2.756.701 | |
| 2014-05-28 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Shares, no par value |
A - Award | 2.866 | 66.653 | 4,49 | ||||
| 2014-05-13 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 469 | 43.041 | 1,10 | ||||
| 2014-05-13 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 2.342 | 42.572 | 5,82 | ||||
| 2014-04-25 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 343 | 32.679 | 1,06 | 51,01 | 17.496 | 1.666.956 | |
| 2014-04-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
| 2014-01-24 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 222 | 32.336 | 0,69 | 67,30 | 14.941 | 2.176.213 | |
| 2013-10-25 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 242 | 32.114 | 0,76 | 61,75 | 14.944 | 1.983.040 | |
| 2013-09-04 |
|
4 | CREE |
CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY) |
A - Award | 4.000 | 4.000 | |||||
| 2013-09-04 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 4.000 | 31.872 | 14,35 | ||||
| 2013-08-16 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 255 | 27.872 | 0,92 | 58,82 | 14.999 | 1.639.431 | |
| 2013-06-06 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Shares, no par value |
F - Taxes | -1.279 | 63.787 | -1,97 | 88,21 | -112.821 | 5.626.651 | |
| 2013-06-03 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Deferred Share Units |
D - Sale to Issuer | -1.319 | 1.281 | -50,73 | 90,81 | -119.778 | 116.328 | |
| 2013-06-03 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
D - Sale to Issuer | -127.128 | 65.066 | -66,15 | 90,81 | -11.544.494 | 5.908.643 | |
| 2013-05-28 |
|
4 | vrx |
Valeant Pharmaceuticals International, Inc.
Common Shares, no par value |
A - Award | 5.022 | 192.194 | 2,68 | ||||
| 2013-05-17 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 563 | 40.230 | 1,42 | ||||
| 2013-05-17 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 2.811 | 39.667 | 7,63 | ||||
| 2013-04-26 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 265 | 27.617 | 0,97 | 56,46 | 14.962 | 1.559.256 | |
| 2013-01-25 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 367 | 27.352 | 1,36 | 40,85 | 14.992 | 1.117.329 | |
| 2012-10-31 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 22 | 8.613 | 0,25 | 91,64 | 2.000 | 789.293 | |
| 2012-10-19 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 518 | 26.985 | 1,96 | 28,92 | 14.981 | 780.406 | |
| 2012-10-02 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 27 | 8.591 | 0,32 | 92,63 | 2.500 | 795.798 | |
| 2012-10-02 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 162 | 8.564 | 1,93 | 92,63 | 15.000 | 793.298 | |
| 2012-09-26 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 16 | 8.402 | 0,19 | 91,75 | 1.500 | 770.905 | |
| 2012-09-26 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 16 | 8.402 | 0,19 | 91,75 | 1.500 | 770.905 | |
| 2012-09-26 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 22 | 8.370 | 0,26 | 91,75 | 2.000 | 767.904 | |
| 2012-09-26 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 5 | 8.348 | 0,06 | 89,31 | 417 | 745.536 | |
| 2012-09-06 |
|
4 | CREE |
CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY) |
A - Award | 4.000 | 4.000 | |||||
| 2012-09-06 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 4.000 | 26.467 | 17,80 | ||||
| 2012-08-10 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 553 | 22.467 | 2,52 | 27,11 | 14.992 | 609.080 | |
| 2012-08-01 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 24 | 8.343 | 0,29 | 82,07 | 2.000 | 684.715 | |
| 2012-08-01 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 18 | 8.319 | 0,21 | 85,30 | 1.500 | 709.584 | |
| 2012-08-01 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 18 | 8.319 | 0,21 | 85,30 | 1.500 | 709.584 | |
| 2012-07-03 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 26 | 8.284 | 0,32 | 94,77 | 2.500 | 785.030 | |
| 2012-07-03 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 158 | 8.257 | 1,95 | 94,77 | 15.000 | 782.530 | |
| 2012-07-03 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 4 | 8.099 | 0,05 | 91,64 | 405 | 742.180 | |
| 2012-06-04 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Shares, no par value |
A - Award | 8.062 | 187.172 | 4,50 | ||||
| 2012-06-01 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
D - Sale to Issuer | -44.634 | 179.110 | -19,95 | ||||
| 2012-05-25 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
S - Sale | -15.000 | 36.856 | -28,93 | 87,72 | -1.315.800 | 3.233.008 | |
| 2012-05-14 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 473 | 51.856 | 0,92 | ||||
| 2012-05-14 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 2.361 | 51.383 | 4,82 | ||||
| 2012-05-02 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 21 | 8.094 | 0,26 | 96,39 | 2.000 | 780.224 | |
| 2012-05-02 |
|
4 | AGN |
ALLERGAN INC
Common Stock |
A - Award | 4.800 | 19.382 | 32,92 | ||||
| 2012-05-02 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 16 | 8.074 | 0,19 | 96,00 | 1.500 | 775.075 | |
| 2012-05-02 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 16 | 8.074 | 0,19 | 96,00 | 1.500 | 775.075 | |
| 2012-04-20 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 500 | 21.914 | 2,33 | 29,97 | 14.985 | 656.763 | |
| 2012-04-03 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 26 | 8.042 | 0,33 | 95,17 | 2.500 | 765.399 | |
| 2012-04-03 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 158 | 8.016 | 2,01 | 95,17 | 15.000 | 762.899 | |
| 2012-04-03 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 4 | 7.859 | 0,05 | 93,00 | 392 | 730.846 | |
| 2012-02-01 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 23 | 7.854 | 0,29 | 87,91 | 2.000 | 690.475 | |
| 2012-02-01 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 17 | 7.832 | 0,22 | 88,06 | 1.500 | 689.650 | |
| 2012-02-01 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 17 | 7.832 | 0,22 | 88,06 | 1.500 | 689.650 | |
| 2012-01-20 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 613 | 21.414 | 2,95 | 24,44 | 14.982 | 523.358 | |
| 2012-01-05 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 28 | 7.798 | 0,36 | 88,42 | 2.500 | 689.458 | |
| 2012-01-05 |
|
4 | AGN |
ALLERGAN INC
Phantom Stock Units |
A - Award | 170 | 7.769 | 2,23 | 88,42 | 15.000 | 686.958 | |
| 2012-01-04 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 220 | 223.744 | 0,10 | ||||
| 2011-10-21 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 514 | 20.801 | 2,53 | 24,30 | 12.490 | 505.464 | |
| 2011-10-03 |
|
4 | VRX |
Valeant Pharmaceuticals International, Inc.
Common Stock, no par value |
A - Award | 277 | 220.690 | 0,13 | ||||
| 2011-09-02 |
|
4 | CREE |
CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY) |
A - Award | 4.000 | 4.000 | |||||
| 2011-09-02 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 4.000 | 20.287 | 24,56 | ||||
| 2011-08-11 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 367 | 16.287 | 2,31 | 34,03 | 12.489 | 554.247 | |
| 2011-04-21 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 315 | 15.920 | 2,02 | 39,67 | 12.496 | 631.546 | |
| 2011-01-21 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 233 | 15.605 | 1,52 | 53,57 | 12.482 | 835.960 | |
| 2010-10-22 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 249 | 15.372 | 1,65 | 50,02 | 12.455 | 768.907 | |
| 2010-08-13 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 209 | 10.123 | 2,11 | 59,78 | 12.494 | 605.153 | |
| 2010-05-18 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 199 | 30.651 | 0,65 | ||||
| 2010-05-18 |
|
4 | EW |
Edwards Lifesciences Corp
Common Stock |
A - Award | 1.987 | 30.452 | 6,98 | ||||
| 2010-04-23 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 164 | 9.914 | 1,68 | 76,19 | 12.495 | 755.348 | |
| 2009-03-10 |
|
4 | CREE |
CREE INC
COMMON STOCK |
P - Purchase | 1.000 | 4.750 | 26,67 | 18,95 | 18.949 | 90.006 | |
| 2008-12-31 |
|
4 | CREE |
CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY) |
A - Award | 3.750 | 3.750 | |||||
| 2008-12-31 |
|
4 | CREE |
CREE INC
COMMON STOCK |
A - Award | 3.750 | 3.750 | |||||
| 2006-01-03 |
|
4 | LOW |
LOWES COMPANIES INC
Phantom Stock |
A - Award | 281 | 7.274 | 4,02 | 66,66 | 18.750 | 484.886 | |
| 2004-06-01 |
|
4 | LOW |
LOWES COMPANIES INC
Non-Qualified Stock Option (right to buy) |
A - Award | 4.000 | 4.000 | |||||
| 2004-05-17 |
|
4 | EW |
EDWARDS LIFESCIENCES CORP
Common Stock |
A - Award | 4.000 | 9.000 | 80,00 |
